Home › Research › Treatments
Association of 3-Year Multidomain Intervention and Omega-3 Supplementation with Frailty Incidence
Guerville F, de Souto Barreto P, Giudici KV, Rolland Y, Vellas B, MAPT/DSA Group.. Journal of the American Geriatrics Society, 2019-06-06
Topic: Risk, prevention and care in population studies
Objectives To assess the associations of long-term lifestyle multidomain intervention (MI) and omega-3 supplementation with frailty level evolution and frailty incidence in community-dwelling older persons. Design Secondary analysis of the randomized controlled Multidomain Alzheimer Preventive Trial. Setting Thirteen memory centers in France and Monaco between 2008 and 2011. Participants A total of 1588 community-dwelling persons aged 70 years or older with memory complaints (without dementia), slow gait speed, or limitation in one instrumental activity of daily living. Intervention A 3-year MI (43 group sessions including cognitive training, physical activity, and nutrition advice and three preventive consultations) plus daily omega-3 fatty acids, MI plus placebo, omega-3 alone, or placebo alone. Measurements The frailty phenotype (unintentional weight loss, exhaustion, low physical activity, slow gait, low handgrip strength: 0 to 5 score, higher is worse; a score of 3 or higher defines frailty) was assessed at baseline, 6, 12, 24, and 36 months. We used mixed-effect models for frailty level (0-5 score as an ordinal variable) and Cox models for frailty incidence. Results No differences were found between the intervention groups and placebo on the 3-year evolution of frailty level. Among 1394 non-frail participants at baseline, frailty incidence occurred in 134 (9.6%) persons: 26 (7.6%) in the MI plus omega-3 group, 34 (10%) in the omega-3 alone group, 31 (8.5%) in the MI plus placebo group, and 43 (12.3%) in the placebo-alone group). No differences regarding frailty incidence were found between intervention groups and placebo. After exclusion of 53 participants with incident frailty during the first year of follow-up, MI plus omega-3 was associated with a lower frailty incidence compared with placebo (hazard ratio = .43; 95% confidence interval = .22-.81). Conclusion In community-dwelling older persons, the combination of a long-term lifestyle MI and omega-3 supplementation did not reduce frailty level or incidence. The reduction of frailty incidence associated with the combined intervention in a sensitivity analysis needs to be further confirmed. J Am Geriatr Soc 67:1700-1706, 2019.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Guerville, F., de Souto Barreto, P., Giudici, K. V., Rolland, Y., Vellas, B., & MAPT/DSA Group. (2019). Association of 3-Year Multidomain Intervention and Omega-3 Supplementation with Frailty Incidence. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.15994
Vancouver
Guerville F, de Souto Barreto P, Giudici KV, Rolland Y, Vellas B, MAPT/DSA Group. Association of 3-Year Multidomain Intervention and Omega-3 Supplementation with Frailty Incidence. Journal of the American Geriatrics Society. 2019. doi:10.1111/jgs.15994. PMID: 31169912.
BibTeX
@article{guerville2019-31169912,
author = {Guerville, F. and de Souto Barreto, P. and Giudici, K. V. and Rolland, Y. and Vellas, B. and {MAPT/DSA Group}},
title = {{Association of 3-Year Multidomain Intervention and Omega-3 Supplementation with Frailty Incidence}},
journal = {Journal of the American Geriatrics Society},
year = {2019},
doi = {10.1111/jgs.15994},
pmid = {31169912},
url = {https://doi.org/10.1111/jgs.15994}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results No differences were found between the intervention groups and placebo on the 3-year evolution of frailty level.
- After exclusion of 53 participants with incident frailty during the first year of follow-up, MI plus omega-3 was associated with a lower frailty incidence compared with placebo (hazard ratio = .43; 95% confidence interval = .22-.81).
- The reduction of frailty incidence associated with the combined intervention in a sensitivity analysis needs to be further confirmed.
Why it matters
Over 3 years, a lifestyle multidomain intervention and omega-3 supplementation showed no difference from placebo in frailty level. A lower frailty incidence was seen for the combined intervention in a sensitivity analysis, which the authors say needs further confirmation; this concerns frailty, not treating or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants53
- Effect size9.6%; 7.6%; 8.5%
- Evidence strengthHigh
How this study scored 64/100
Published in a peer-reviewed journal, and it is a randomised controlled trial. We have no data on senior author's track record, so that was left out: it earned 61 of the 96 points we could judge it on, which is 64 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of the American Geriatrics Society) |
| Journal's citation record | 3 / 4 | Journal of the American Geriatrics Society: journal h-index 344 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomised controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 53 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | 3 / 7 | Cited 30 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.3 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 2 / 6 | Cited 1.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 1 / 4 | Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31169912) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 61 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 61 of the 96 points we could judge it on is 64 out of 100. |
| Total | 64 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Treatments
Also tagged “palliative”
858 studies in the library carry the topic tag “palliative”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 858 tagged studies.